Medically reviewed by William Truswell, MD Clubbed nails, also known as digital clubbing or Hippocratic fingers, describe a ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19 ... Details About Rare Second Cancers Related to CAR-T Therapy June 12 ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Recent studies show that HIV patients are 10 to 20 times more likely to develop lymphoma compared to individuals without HIV.

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Non-Hodgkin's lymphoma invades the brain, the vitreous body and nerves of the eye, the meninges, and the nerve roots of brain and spine, leading to the development of a primary CNS lymphoma.

HIV is spread by bodily fluids such as blood, breast milk or semen. It gradually weakens the body’s immune system and makes ...

A generation has passed since the world saw the peak in AIDS-related deaths. Those deaths — agonizing, from diseases or infections the body might otherwise fight off — sent loved ones into the ...